logo
    Docs
 

Unmet Medical Need: Efo/glomerular Disease


1. Disease Summary:

Glomerular diseases encompass a range of conditions that primarily affect the glomeruli, the filtering units of the kidneys. These diseases can lead to significant kidney damage and are often characterized by symptoms such as proteinuria (excess protein in urine), hematuria (blood in urine), and varying degrees of kidney dysfunction. Common types of glomerular diseases include IgA nephropathy, focal segmental glomerulosclerosis (FSGS), membranous nephropathy, and lupus nephritis. These conditions can progress to chronic kidney disease (CKD) and ultimately end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation.

2. Global Prevalence and Disease Burden:

Globally, chronic kidney disease affects approximately 700 million people, with glomerular diseases being a significant contributor to this burden. For instance, the prevalence of FSGS has been reported at around 26.1% in certain populations, while IgA nephropathy is the most common primary glomerular disease worldwide (PMID: 37869232). The economic impact of glomerular diseases is substantial, with CKD projected to rise in the list of causes of death from 16th place in 2016 to 5th place by 2040, leading to increased healthcare costs and loss of productivity (source: Global Burden of Disease Study).

3. Unmet Medical Need:

Despite advancements in understanding glomerular diseases, there remains a significant unmet medical need for effective treatments. Key areas of unmet need include:
  • Efficacy of Current Treatments: Many patients do not respond adequately to existing therapies, such as corticosteroids and immunosuppressants. For example, 40-50% of patients with FSGS fail to respond to current treatments, leading to progressive renal failure (source: Emerging drugs for treatment of focal segmental glomerulosclerosis).
  • Safety and Side Effects: Current treatments often come with severe side effects, including increased risk of infections, diabetes, and hypertension. The long-term use of corticosteroids can lead to significant morbidity (source: Current treatment of IgA nephropathy).
  • Personalized Treatment Approaches: There is a lack of personalized treatment options that consider individual patient characteristics and disease mechanisms. The need for biomarkers to guide treatment decisions is critical, as many patients experience disease progression despite treatment (source: Unmet Needs in Current IgAN Treatment).
  • Access to Care: Socioeconomic factors significantly influence the incidence and management of glomerular diseases. Patients from lower socioeconomic backgrounds often have limited access to healthcare resources, leading to worse outcomes (PMID: 32079609).

4. Current Treatment Options:

Current treatment options for glomerular diseases vary by specific condition but generally include:
  • Corticosteroids: Often used as first-line therapy for conditions like IgA nephropathy and FSGS. While they can reduce proteinuria, their long-term efficacy is debated, and they are associated with significant side effects (source: Current treatment of IgA nephropathy).
  • Immunosuppressants: Drugs such as cyclophosphamide and mycophenolate mofetil are used in more severe cases. However, these treatments can lead to increased risk of infections and other complications (source: Emerging drugs for treatment of focal segmental glomerulosclerosis).
  • Supportive Care: Management of hypertension and diabetes is crucial in patients with glomerular diseases. However, this approach does not address the underlying disease mechanisms (source: An Update on Current Therapeutic Options in IgA Nephropathy).

5. Current Clinical Trials:

Numerous clinical trials are underway to explore new treatment options for glomerular diseases. For example:
  • Sparsentan: A dual endothelin receptor and angiotensin receptor blocker is being investigated for its efficacy in treating FSGS (source: Full article: Sparsentan clinical trials in glomerular diseases).
  • Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: These agents are being studied for their potential benefits in patients with IgA nephropathy, showing promise in reducing proteinuria and slowing disease progression (source: The Treatment of Primary IgA Nephropathy: Change, Change, Change).
  • Targeted Therapies: Research is focusing on therapies that target specific pathways involved in glomerular diseases, such as complement inhibition and B-cell depletion strategies (source: Targeted therapy in glomerular diseases).

6. Additional Context:

The landscape of glomerular disease treatment is evolving, with a growing emphasis on personalized medicine and the development of novel therapies. However, significant gaps remain in the effective management of these conditions. Addressing the unmet medical needs in glomerular diseases is crucial not only for improving patient outcomes but also for reducing the overall burden on healthcare systems. As research continues to advance, there is hope for more effective and safer treatment options that can significantly alter the course of these debilitating diseases.